Radioactive Iodine (RAI) Therapy: What to Expect

Radioactive iodine (I-131) is a swallowed capsule or liquid that destroys thyroid cells. It is used to permanently calm Graves hyperthyroidism and to ablate any remaining thyroid tissue after surgery for differentiated thyroid cancer. Preparation usually includes a 1–2 week low-iodine diet; after treatment, patients follow brief isolation rules for several days. Hypothyroidism within 3–6 months is the expected outcome, and pregnancy is an absolute contraindication.

Why and how RAI works

The thyroid gland is the only tissue in the body that actively concentrates iodine — it uses iodine to build thyroid hormone. Radioactive iodine (the isotope iodine-131, or I-131) exploits this. Once swallowed, it is absorbed by the gut and then selectively taken up by thyroid cells, where the short-range beta radiation it emits destroys the cells from inside [C1][C2][C4].

Because non-thyroid tissue picks up very little I-131, the radiation dose to the rest of the body is small and the therapy has been used safely since the 1940s [C1][C2]. The two settings where endocrinologists use it are very different in dose and intent [C1][C2][C4]:

• Graves hyperthyroidism — a moderate fixed or weight-based dose, designed to render the gland hypothyroid (definitive cure of the overactivity).
• Differentiated thyroid cancer (papillary, follicular) after thyroidectomy — a higher dose, designed to destroy any residual thyroid cells and microscopic cancer that surgery cannot remove.

It is not used for medullary or anaplastic thyroid cancer (those cells do not concentrate iodine) and it is not first-line for Hashimoto hypothyroidism, multinodular goiter without hyperfunction, or thyroid nodules that are benign [C1][C2].

Clinical pattern and timeline

The preparation, procedure, and recovery follow a similar template in both settings, with cancer ablation being more intensive [C1][C2]:

• 1–2 weeks before: Low-iodine diet to "starve" the thyroid of competing dietary iodine so it greedily takes up the radioactive dose. Iodized salt, dairy, seafood, seaweed, and many processed foods are restricted [C2].
• For Graves: Antithyroid drugs (methimazole) are usually stopped several days before; beta-blockers may continue [C1].
• For cancer: TSH must be high (>30 mIU/L) to drive uptake. Two methods — either withdraw levothyroxine for 4–6 weeks (causes temporary hypothyroidism) or use two days of recombinant TSH injections (Thyrogen, no withdrawal needed) [C2].
• Day of treatment: A swallowed capsule or drink, given in nuclear medicine. The visit is brief; no anesthesia [C1][C2].
• Days 1–7 after: Isolation rules to limit radiation exposure to others. Typical instructions: avoid prolonged close contact with adults, avoid pregnant women and young children entirely, sleep alone, flush twice, drink water, and avoid sharing utensils. Specific durations vary by dose and local regulation [C1][C2].
• Weeks to months after: Hyperthyroid symptoms gradually subside in Graves; hypothyroidism develops in 3–6 months in most patients and is treated with daily levothyroxine [C1][C3]. In cancer patients, levothyroxine is restarted right after RAI at TSH-suppressive doses [C2].

The temporary hypothyroidism of cancer prep (when withdrawal is used) is genuinely uncomfortable — fatigue, brain fog, weight gain over weeks. Recombinant TSH avoids this and is now widely preferred when available [C2][C4].

What recovers after RAI on adequate levothyroxine

In Graves disease, RAI turns an overactive gland into an underactive one — the expected, intentional result. Once levothyroxine is dosed to a stable TSH in the normal range, most of the hyperthyroid symptoms reverse [C1][C3][C8]:

• Heart palpitations, tremor, heat intolerance, anxiety — usually resolve within weeks of becoming euthyroid
• Weight stabilizes; some patients regain weight lost during hyperthyroidism, occasionally beyond baseline [C1]
• Bone density stops being eroded by excess thyroid hormone [C1]
• Menstrual cycles and fertility normalize once thyroid hormone is in range [C1][C6]

In thyroid cancer ablation, the goal is not symptom recovery (the cancer is usually low-symptom) but disease-free survival. Thyroglobulin and neck ultrasound surveillance over months and years confirm that residual disease is gone [C2][C4].

Thyroid eye disease (Graves orbitopathy) deserves a separate note: RAI can worsen it transiently in 15–30% of patients with active eye disease, especially smokers. Endocrinologists often pre-treat with oral steroids or pick surgery or long-term antithyroid drugs instead for moderate-to-severe orbitopathy [C1][C7].

When symptoms or problems persist

Several scenarios warrant follow-up after RAI [C1][C2][C3]:

1. Persistent hyperthyroidism in Graves. Up to 15–20% of Graves patients need a second RAI dose if the gland is not adequately ablated by 6 months. Free T4 and TSH at 6–8 weeks, then at 3 and 6 months, guide the decision [C1].
2. Hypothyroid symptoms before levothyroxine kicks in. Fatigue, cold intolerance, and weight gain in the months after RAI are expected as the gland fails. Starting levothyroxine promptly and titrating to TSH-target shortens this phase [C1][C3].
3. Dry mouth, salty taste, or salivary gland swelling. The salivary glands also concentrate small amounts of I-131. Mild sialadenitis is common after higher cancer-ablation doses and usually resolves; sucking on sour candies and staying hydrated during and after treatment reduces risk [C2].
4. Worsening eye symptoms (Graves orbitopathy). New double vision, eye pain, or worsening proptosis after RAI requires urgent ophthalmology referral [C1].
5. Persistent or rising thyroglobulin in cancer patients suggests residual or recurrent disease and triggers further imaging and possibly additional RAI [C2][C4].
6. Fertility concerns. A single therapeutic dose of I-131 does not appear to reduce female fertility long-term, and male fertility is preserved at standard cancer doses; very high cumulative doses can transiently reduce sperm counts [C2][C4]. Pregnancy should be deferred 6–12 months after treatment to confirm cancer remission and stabilize thyroid replacement [C2][C6].

What does NOT change the outcome

A few popular beliefs and add-ons have no clinical evidence for RAI [C1][C2][C8]:

• "Detox" protocols to clear residual radiation after RAI — the body excretes I-131 through urine on its own; staying hydrated is enough, no supplement accelerates this.
• High-dose vitamin C or antioxidants during preparation — no trial shows improved ablation success or reduced side effects, and very high vitamin C can interfere with the low-iodine prep window.
• Iodine supplements or kelp before RAI — would completely defeat the low-iodine diet. Stop any iodine-containing multivitamins 1–2 weeks before, longer if amiodarone or recent iodinated CT contrast [C1][C2].
• Refusing levothyroxine after Graves RAI — hypothyroidism is the goal, and untreated hypothyroidism carries real cardiovascular and cognitive cost [C3][C8]. There is no nutritional or herbal substitute for thyroid hormone.

Practical guidelines

1. Confirm the indication with your endocrinologist — RAI is excellent for Graves and differentiated thyroid cancer, not for Hashimoto hypothyroidism or benign nodules without hyperfunction [C1][C2].
2. Plan the low-iodine diet 1–2 weeks before. Your treatment team will provide a specific food list — broadly: no iodized salt, no dairy, no seafood/seaweed, no egg yolks, no red dye #3, and avoid iodinated contrast for 4–6 weeks beforehand [C2].
3. Rule out pregnancy before any therapeutic dose. A pregnancy test within 72 hours of treatment is standard. Effective contraception for 6–12 months after is recommended [C2][C6].
4. Follow the isolation instructions exactly. Distances, durations, and waste-handling rules are calibrated to keep family and the public below regulatory radiation limits. Your nuclear medicine team will give written instructions [C1][C2].
5. Restart levothyroxine on the schedule your endocrinologist sets — immediately after RAI for cancer (TSH-suppressive dose) or once TSH starts rising for Graves (replacement dose) [C2][C3].
6. Get follow-up labs at 6–8 weeks and 3 months. TSH and free T4 (plus thyroglobulin in cancer) guide dose adjustments [C1][C2][C3].

Frequently asked questions

Will radioactive iodine cure my Graves disease? RAI permanently resolves hyperthyroidism in most patients — about 80–90% with a single dose, the rest with a second dose if needed [C1]. It does not "cure" the underlying autoimmune process; the antibodies persist, but with the gland ablated they have nothing to drive [C1][C7].

Will I be radioactive afterwards? Briefly, yes. You will follow isolation precautions for several days to a couple of weeks depending on the dose. I-131 has an 8-day half-life and is excreted in urine, so radioactivity drops quickly [C1][C2].

Can I have RAI if I want to get pregnant? Not while planning a current pregnancy. Pregnancy is an absolute contraindication during RAI [C6]. After treatment, your endocrinologist will recommend deferring pregnancy for 6–12 months to confirm remission and stabilize thyroid hormone replacement [C2][C6].

Does RAI cause cancer? The cancer doses used to ablate residual thyroid tissue are far higher than diagnostic uses, but large registries show very small absolute increases in second cancers, mostly leukemia and salivary gland tumors at very high cumulative doses [C2][C4]. For most patients, the benefit of RAI vastly outweighs this risk.

Will I need thyroid hormone forever after RAI? In Graves, yes — once the gland is ablated, daily levothyroxine is lifelong [C1][C3]. In cancer ablation, yes — the thyroidectomy already removed the gland; levothyroxine continues lifelong, often at TSH-suppressive doses [C2].

Bottom line

Radioactive iodine is one of the most established and effective treatments in endocrinology, used since the 1940s for Graves hyperthyroidism and after thyroidectomy for differentiated thyroid cancer [C1][C2]. Preparation includes a low-iodine diet and, for cancer, a TSH-stimulation step; the treatment itself is a swallowed dose followed by short-term isolation [C1][C2]. Hypothyroidism within 3–6 months is the expected outcome in Graves and the goal in cancer — managed with daily levothyroxine [C1][C3][C8]. Pregnancy is an absolute contraindication, and most patients should defer pregnancy 6–12 months after treatment [C2][C6]. Your endocrinologist will tailor the dose and the follow-up schedule.